OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stock

OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno purchased 33,898 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the transaction, the director now directly owns 69,054 shares in the company, valued at approximately $203,709.30. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

OncoCyte Stock Performance

Shares of NASDAQ:OCX opened at $2.53 on Tuesday. The business has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $3.06. OncoCyte Co. has a 1 year low of $2.08 and a 1 year high of $6.80.

Analysts Set New Price Targets

OCX has been the subject of a number of recent analyst reports. Benchmark restated a “speculative buy” rating and issued a $5.00 price objective on shares of OncoCyte in a research note on Monday. StockNews.com initiated coverage on OncoCyte in a research note on Friday. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OCX. Raymond James Financial Services Advisors Inc. bought a new position in shares of OncoCyte during the 1st quarter worth $25,000. Vanguard Group Inc. grew its stake in shares of OncoCyte by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock worth $5,940,000 after acquiring an additional 90,534 shares during the period. DCF Advisers LLC grew its stake in shares of OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock worth $37,000 after acquiring an additional 13,000 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of OncoCyte by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock worth $686,000 after acquiring an additional 24,964 shares during the period. Finally, LPL Financial LLC grew its stake in shares of OncoCyte by 58.1% during the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock worth $98,000 after acquiring an additional 40,000 shares during the period. Institutional investors own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.